BRPI0416924A - preparação farmacêutica para tratamento hormonal contìnuo durante um perìodo de mais do que 21-28 dias compreendendo duas composições de estrogênio e/ou progestina - Google Patents
preparação farmacêutica para tratamento hormonal contìnuo durante um perìodo de mais do que 21-28 dias compreendendo duas composições de estrogênio e/ou progestinaInfo
- Publication number
- BRPI0416924A BRPI0416924A BRPI0416924-7A BRPI0416924A BRPI0416924A BR PI0416924 A BRPI0416924 A BR PI0416924A BR PI0416924 A BRPI0416924 A BR PI0416924A BR PI0416924 A BRPI0416924 A BR PI0416924A
- Authority
- BR
- Brazil
- Prior art keywords
- days
- estrogen
- pharmaceutical preparation
- period
- progestin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"PREPARAçãO FARMACêUTICA PARA TRATAMENTO HORMONAL CONTìNUO DURANTE UM PERìODO DE MAIS DO QUE 21-28 DIAS COMPREENDENDO DUAS COMPOSIçõES DE ESTRÈGENIO E/OU PROGESTINA". Uma preparação farmacêutica para se obter um tratamento hormonal contínuo durante um período de tempo desejado mais longo do que 21-28 dias compreendendo uma primeira composição contendo pelo menos um estrogênio e/ou pelo menos uma progestina em uma quantidade predeterminada a ser administrada nos primeiros 21-28 dias e uma segunda composição que contém pelo menos um estrogênio e/ou pelo menos uma progestina em uma quantidade predeterminada mais alta do que a quantidade da primeira composição e compreende uma seqüência de mono- ou multifases das dosagens farmacêuticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03090405A EP1535618A1 (en) | 2003-11-26 | 2003-11-26 | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
PCT/EP2004/013545 WO2005051400A1 (en) | 2003-11-26 | 2004-11-20 | Extended use combination comprising estrogens and progestins |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0416924A true BRPI0416924A (pt) | 2007-01-16 |
Family
ID=34443011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0416924-7A BRPI0416924A (pt) | 2003-11-26 | 2004-11-20 | preparação farmacêutica para tratamento hormonal contìnuo durante um perìodo de mais do que 21-28 dias compreendendo duas composições de estrogênio e/ou progestina |
Country Status (22)
Country | Link |
---|---|
US (1) | US20080234240A1 (pt) |
EP (3) | EP1535618A1 (pt) |
JP (1) | JP2007512291A (pt) |
KR (1) | KR20060126671A (pt) |
CN (1) | CN1905885A (pt) |
AR (1) | AR046671A1 (pt) |
AU (1) | AU2004292778A1 (pt) |
BR (1) | BRPI0416924A (pt) |
CA (1) | CA2547051A1 (pt) |
CR (1) | CR8450A (pt) |
EA (1) | EA200600964A1 (pt) |
EC (1) | ECSP066674A (pt) |
GT (1) | GT200400242A (pt) |
IL (1) | IL175858A0 (pt) |
NO (1) | NO20062945L (pt) |
PA (1) | PA8618301A1 (pt) |
PE (1) | PE20051038A1 (pt) |
RS (1) | RS20060348A (pt) |
TW (1) | TW200529862A (pt) |
UY (1) | UY28631A1 (pt) |
WO (1) | WO2005051400A1 (pt) |
ZA (1) | ZA200605224B (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070111975A1 (en) * | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
DE102004062182B4 (de) * | 2004-12-20 | 2007-06-06 | Bayer Schering Pharma Ag | Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff |
JP2009501722A (ja) * | 2005-07-15 | 2009-01-22 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | ドロスピレノン含有経皮用薬剤供給装置及びその供給方法 |
EP1774970A1 (de) * | 2005-10-13 | 2007-04-18 | Bayer Schering Pharma AG | Verfahren zur Herstellung eines einphasigen pharmazeutischen Präparates zur Therapie der dysfunktionellen uterinen Blutung, enthaltend Ethinylestradiol und Dienogest |
DE102005056527A1 (de) * | 2005-11-25 | 2007-07-12 | Grünenthal GmbH | Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels |
WO2008018872A1 (en) * | 2006-08-10 | 2008-02-14 | Drugtech Corporation | Therapeutic methods of using estrogen compositions |
EP1977752A1 (de) * | 2007-03-01 | 2008-10-08 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Zubereitung zur Verminderung der Endometriose |
DE102007011105A1 (de) * | 2007-03-02 | 2008-09-04 | Bayer Schering Pharma Aktiengesellschaft | Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然の併用ホルモン補充療法剤及び療法 |
CN104546870B (zh) * | 2015-01-27 | 2018-01-12 | 唐凡兰 | 一种避孕药 |
HUE054551T2 (hu) | 2015-06-18 | 2021-09-28 | Estetra Sprl | Ösztetrolt tartalmazó, szájban diszpergálódó tabletta |
NO3106148T3 (pt) | 2015-06-18 | 2018-08-11 | ||
WO2016203009A1 (en) | 2015-06-18 | 2016-12-22 | Mithra Pharmaceuticals S.A. | Orodispersible tablet containing estetrol |
GEP20217243B (en) | 2015-06-18 | 2021-04-26 | Sprl Estetra | Orodispersible dosage unit containing an estetrol component |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
EP3435977A4 (en) | 2016-04-01 | 2019-10-16 | Therapeuticsmd, Inc. | PHARMACEUTICAL COMPOSITION OF STEROID HORMONE |
KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
JP2018083806A (ja) * | 2016-11-11 | 2018-05-31 | 持田製薬株式会社 | 月経困難症治療用組成物 |
UY38075A (es) * | 2018-02-07 | 2019-10-01 | Estetra Sprl | Composiciones anticonceptivas con efectos cardiovasculares reducidos |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
CL2021001762A1 (es) * | 2021-07-01 | 2022-01-21 | Univ Pontificia Catolica Chile | Uso del estetrol como tratamiento para la endometriosis |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3969502A (en) * | 1972-04-14 | 1976-07-13 | Schering Aktiengesellschaft | Method for contraception by the administration of sequential contraceptive preparations |
AU581486B2 (en) * | 1985-12-30 | 1989-02-23 | Warner-Lambert Company | Graduated estrogen contraceptive |
US5010070A (en) * | 1987-06-15 | 1991-04-23 | Warner-Lambert Company | Graduated estrogen contraceptive |
DK174724B1 (da) | 1986-07-15 | 2003-10-06 | Wyeth Corp | Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet |
HU214598B (hu) * | 1987-09-24 | 1998-04-28 | Jencap Research Ltd | Eljárás fogamzásgátló és hormonterápiához alkalmazható, ösztrogént és progesztint tartalmazó gyógyszerkészítmények előállítására |
US5276022A (en) * | 1987-09-24 | 1994-01-04 | Jencap Research Ltd. | Hormone preparation and method |
IE71203B1 (en) * | 1990-12-13 | 1997-02-12 | Akzo Nv | Low estrogen oral contraceptives |
DE4411585A1 (de) * | 1994-03-30 | 1995-10-05 | Schering Ag | Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption |
DE19540253C2 (de) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
DE19549264A1 (de) * | 1995-12-23 | 1997-06-26 | Schering Ag | Verfahren und Kit zur Kontrazeption |
AU4043597A (en) * | 1996-07-26 | 1998-02-20 | American Home Products Corporation | Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen |
US6028064A (en) * | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
DE19654609A1 (de) * | 1996-12-20 | 1998-06-25 | Schering Ag | Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder |
US5898032A (en) * | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
AU9028098A (en) | 1997-08-27 | 1999-03-16 | Ortho Pharmaceutical Corporation | Combinations of endometrial sparing progestins and endometrial atrophizing progestins with estrogens, in oral contraception |
US20020193356A1 (en) * | 2001-05-23 | 2002-12-19 | Van Beek Agatha Antonia Magdalena | Means and method for hormonal contraception |
WO2003006027A1 (en) * | 2001-07-13 | 2003-01-23 | Schering Aktiengesellschaft | Combination of drospirenone and an estrogen sulphamate for hrt |
HU230759B1 (hu) | 2001-12-05 | 2018-03-28 | Teva Women's Health, Inc. | Teherbeesés megakadályozására és menstruációs tünetek enyhítésére vagy kiküszöbölésére alkalmas orális készítmények |
-
2003
- 2003-11-26 EP EP03090405A patent/EP1535618A1/en not_active Withdrawn
-
2004
- 2004-11-20 KR KR1020067012707A patent/KR20060126671A/ko not_active Application Discontinuation
- 2004-11-20 JP JP2006540407A patent/JP2007512291A/ja active Pending
- 2004-11-20 WO PCT/EP2004/013545 patent/WO2005051400A1/en active Application Filing
- 2004-11-20 RS YUP-2006/0348A patent/RS20060348A/sr unknown
- 2004-11-20 EP EP04803349A patent/EP1689409A1/en not_active Ceased
- 2004-11-20 EP EP08020987A patent/EP2044942A1/en not_active Withdrawn
- 2004-11-20 CN CNA2004800410231A patent/CN1905885A/zh active Pending
- 2004-11-20 CA CA002547051A patent/CA2547051A1/en not_active Abandoned
- 2004-11-20 US US10/584,045 patent/US20080234240A1/en not_active Abandoned
- 2004-11-20 BR BRPI0416924-7A patent/BRPI0416924A/pt not_active IP Right Cessation
- 2004-11-20 AU AU2004292778A patent/AU2004292778A1/en not_active Abandoned
- 2004-11-20 EA EA200600964A patent/EA200600964A1/ru unknown
- 2004-11-23 UY UY28631A patent/UY28631A1/es not_active Application Discontinuation
- 2004-11-25 PE PE2004001155A patent/PE20051038A1/es not_active Application Discontinuation
- 2004-11-25 GT GT200400242A patent/GT200400242A/es unknown
- 2004-11-25 PA PA20048618301A patent/PA8618301A1/es unknown
- 2004-11-26 TW TW093136571A patent/TW200529862A/zh unknown
- 2004-11-26 AR ARP040104377A patent/AR046671A1/es not_active Application Discontinuation
-
2006
- 2006-05-23 IL IL175858A patent/IL175858A0/en unknown
- 2006-06-13 CR CR8450A patent/CR8450A/es not_active Application Discontinuation
- 2006-06-23 EC EC2006006674A patent/ECSP066674A/es unknown
- 2006-06-23 ZA ZA200605224A patent/ZA200605224B/xx unknown
- 2006-06-23 NO NO20062945A patent/NO20062945L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20062945L (no) | 2006-08-23 |
ECSP066674A (es) | 2006-10-25 |
EP2044942A1 (en) | 2009-04-08 |
UY28631A1 (es) | 2005-06-30 |
TW200529862A (en) | 2005-09-16 |
EA200600964A1 (ru) | 2006-10-27 |
JP2007512291A (ja) | 2007-05-17 |
CN1905885A (zh) | 2007-01-31 |
AU2004292778A1 (en) | 2005-06-09 |
AR046671A1 (es) | 2005-12-14 |
RS20060348A (en) | 2008-08-07 |
ZA200605224B (en) | 2009-10-28 |
IL175858A0 (en) | 2006-10-05 |
KR20060126671A (ko) | 2006-12-08 |
CA2547051A1 (en) | 2005-06-09 |
WO2005051400A1 (en) | 2005-06-09 |
US20080234240A1 (en) | 2008-09-25 |
CR8450A (es) | 2007-06-06 |
EP1689409A1 (en) | 2006-08-16 |
GT200400242A (es) | 2006-01-18 |
PA8618301A1 (es) | 2006-05-16 |
EP1535618A1 (en) | 2005-06-01 |
PE20051038A1 (es) | 2006-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0416924A (pt) | preparação farmacêutica para tratamento hormonal contìnuo durante um perìodo de mais do que 21-28 dias compreendendo duas composições de estrogênio e/ou progestina | |
KR900701277A (ko) | 피임 시스템 및 방법 | |
DK0836506T4 (da) | Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen | |
BR0109150A (pt) | Método para administração de um anestésico local a um indivìduo em necessidade de um efeito anestésico local, emplastro, composição, e, recipiente | |
BR9912466A (pt) | Utilização de sulfamatos de estrogênio biogênicos na terapia de reposição hormonal | |
NO986104D0 (no) | Progesteron-anti-progesteron regimer | |
KR960706344A (ko) | 호르몬 피임 및/또는 여드름 치료 수단 및 방법(means and method for hormonal contraception and/or the treatment of acne) | |
HUP0204137A2 (hu) | Fulvesztrantot tartalmazó gyógyászati készítmény | |
HRP20070188B1 (hr) | Farmaceutska kombinacija etinilestradiola i drospirenona za upotrebu kao kontracepcijskog sredstva | |
KR920011515A (ko) | 피임제제 | |
BR0109334A (pt) | Terapia de reposição hormonal | |
ATE248853T1 (de) | Pharmazeutische zusammensetzungen mit estra-1,3, 5(10)-trien-derivaten | |
DE69902875D1 (de) | Tts enthaltend ein antioxidans | |
GB8830380D0 (en) | New derivatives of 17beta-oh 19-nor steroids substituted in the 17alpha position,their preparation,their use as medicaments and pharmaceutical compositions | |
BR0208652A (pt) | Composição parenteral reconstituìvel contendo um inibidor de cox-2 | |
MX2007013137A (es) | Regimen anticonceptivo con dosificacion de estrogeno ampliada. | |
NZ591627A (en) | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology | |
HRP20100513T1 (en) | Multi-phase contraceptive preparation based on a natural estrogen | |
EA200301022A1 (ru) | Гормональная заместительная терапия | |
BR0008076A (pt) | 16-hidroxiestratrienos como estrogênios de efeito seletivo | |
WO2005092441A3 (en) | Extended cycle multiphasic oral contraceptive method | |
BR9712274A (pt) | Composição hormonal consistindo de um composto de estrogênio e um composto progestacional | |
NO20072687L (no) | Farmasoytisk prevensjonspreparat | |
PT927031E (pt) | Composicao farmaceutica que contem nimesulide para administracao por via oral | |
BR0309621A (pt) | Uso de estrógenos conjugados em combinação com trimegestona na terapia de substituição de hormÈnios |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |